{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:14:44Z","timestamp":1790691284619,"version":"4.1.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cjca.2016.01.027","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T00:00:42Z","timestamp":1454371242000},"page":"863-870.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond"],"prefix":"10.1016","volume":"32","author":[{"given":"Rohit","family":"Moudgil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.H.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2016.01.027_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib2","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.01.027_bib3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib4","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.1998.16.2.545","article-title":"Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia","volume":"16","author":"Nysom","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11764-011-0186-6","article-title":"Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood","volume":"6","author":"Vandecruys","year":"2012","journal-title":"J\u00a0Cancer Surviv"},{"key":"10.1016\/j.cjca.2016.01.027_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archinternmed.2010.233","article-title":"Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study","volume":"170","author":"van der Pal","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib9","first-page":"5969","article-title":"DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA","volume":"49","author":"Bodley","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.cjca.2016.01.027_bib10","first-page":"41","article-title":"DNA topoisomerases: harnessing and constraining energy to govern chromosome topology","volume":"41","author":"Schoeffler","year":"2008","journal-title":"Q\u00a0Rev Biophys"},{"key":"10.1016\/j.cjca.2016.01.027_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/emboj\/cdg008","article-title":"Structure of the topoisomerase VI-B subunit: implications for type II topoisomerase mechanism and evolution","volume":"22","author":"Corbett","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.cjca.2016.01.027_bib12","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib13","doi-asserted-by":"crossref","first-page":"H1273","DOI":"10.1152\/ajpheart.00738.2005","article-title":"DNA damage is an early event in doxorubicin-induced cardiac myocyte death","volume":"291","author":"L\u2019Ecuyer","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cjca.2016.01.027_bib14","doi-asserted-by":"crossref","first-page":"H1956","DOI":"10.1152\/ajpheart.00407.2008","article-title":"ERKs\/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes","volume":"295","author":"Liu","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cjca.2016.01.027_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12012-007-0023-3","article-title":"Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?","volume":"7","author":"Hasinoff","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.cjca.2016.01.027_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0041-008X(88)90226-8","article-title":"Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats","volume":"92","author":"Herman","year":"1988","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib17","first-page":"15","article-title":"Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity","volume":"25","author":"Herman","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s002800050048","article-title":"Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats","volume":"45","author":"Herman","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF00685888","article-title":"Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity","volume":"32","author":"Herman","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib20","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-011-1587-y","article-title":"The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats","volume":"68","author":"Rao","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib21","first-page":"22","article-title":"Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects","volume":"25","author":"Imondi","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","article-title":"Cardiac toxicity in breast cancer survivors: review of potential cardiac problems","volume":"14","author":"Bird","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2016.01.027_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2016.01.027_bib29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/378386a0","article-title":"Multiple essential functions of neuregulin in development","volume":"378","author":"Meyer","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2016.01.027_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/rp.59.1.1","article-title":"Essential roles of Her2\/erbB2 in cardiac development and function","volume":"59","author":"Negro","year":"2004","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.cjca.2016.01.027_bib31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib32","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2016.01.027_bib33","doi-asserted-by":"crossref","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","article-title":"Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes","volume":"273","author":"Zhao","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"suppl 6","key":"10.1016\/j.cjca.2016.01.027_bib34","doi-asserted-by":"crossref","first-page":"vi26","DOI":"10.1093\/annonc\/mdm220","article-title":"Lapatinib in breast cancer","volume":"18","author":"Bilancia","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib35","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","article-title":"Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab","volume":"23","author":"Lenihan","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib37","doi-asserted-by":"crossref","first-page":"10607","DOI":"10.1073\/pnas.0701286104","article-title":"Activation of AMP-activated protein kinase by human EGF receptor 2\/EGF receptor tyrosine kinase inhibitor protects cardiac cells","volume":"104","author":"Spector","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2016.01.027_bib38","doi-asserted-by":"crossref","first-page":"12268","DOI":"10.3390\/ijms131012268","article-title":"Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics","volume":"13","author":"Hervent","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2016.01.027_bib39","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjca.2016.01.027_bib41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C","article-title":"The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy","volume":"71","author":"Robben","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oxfordjournals.annonc.a057963","article-title":"5-fluorouracil cardiotoxicity: the risk of rechallenge","volume":"2","author":"Labianca","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"key":"10.1016\/j.cjca.2016.01.027_bib45","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E","article-title":"Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer","volume":"72","author":"Schober","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/030089160108700317","article-title":"Acute cardiotoxicity during capecitabine treatment: a case report","volume":"87","author":"Bertolini","year":"2001","journal-title":"Tumori"},{"key":"10.1016\/j.cjca.2016.01.027_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/106002809402800314","article-title":"Fluorouracil cardiotoxicity","volume":"28","author":"Anand","year":"1994","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjca.2016.01.027_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(19880101)61:1<36::AID-CNCR2820610108>3.0.CO;2-6","article-title":"5-Fluorouracil-associated cardiotoxicity","volume":"61","author":"Freeman","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/annonc\/mdf035","article-title":"Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil","volume":"13","author":"Frickhofen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib51","first-page":"81","article-title":"Endothelin-1 and 5-fluorouracil-induced cardiotoxicity","volume":"45","author":"Porta","year":"1998","journal-title":"Neoplasma"},{"key":"10.1016\/j.cjca.2016.01.027_bib52","first-page":"3028","article-title":"In\u00a0vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.cjca.2016.01.027_bib53","first-page":"41","article-title":"Capecitabine-related cardiotoxicity: recognition and management","volume":"6","author":"Saif","year":"2008","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A\u00a0systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.cjca.2016.01.027_bib55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cjca.2016.01.027_bib56","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib57","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib58","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib59","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib60","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib61","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib62","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib63","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A\u00a0randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib65","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib66","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-010-0815-4","article-title":"Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis","volume":"66","author":"An","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib67","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2016.01.027_bib69","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib70","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.027_bib71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in\u00a0vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cjca.2016.01.027_bib72","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1158\/1078-0432.CCR-05-2257","article-title":"Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in\u00a0vivo model of pancreatic cancer","volume":"12","author":"Camp","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2016.01.027_bib73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib74","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.115.05435","article-title":"Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib","volume":"66","author":"Lankhorst","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2016.01.027_bib75","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.027_bib76","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cjca.2016.01.027_bib77","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.cjca.2016.01.027_bib78","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2016.01.027_bib79","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib80","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib81","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib82","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","article-title":"Bradycardia during therapy for multiple myeloma with thalidomide","volume":"93","author":"Fahdi","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.027_bib83","first-page":"587","article-title":"Thalidomide causes sinus bradycardia in ALS","volume":"255","author":"Meyer","year":"2008","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cjca.2016.01.027_bib84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0006-8993(02)03178-5","article-title":"Tumor necrosis factor-alpha inhibits physiologically identified dorsal motor nucleus neurons in\u00a0vivo","volume":"951","author":"Emch","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.cjca.2016.01.027_bib85","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/10428190009087019","article-title":"Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy","volume":"38","author":"Huan","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cjca.2016.01.027_bib86","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-133-11-200012050-00012","article-title":"Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia","volume":"133","author":"Ohnishi","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib87","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"Barbey","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib88","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","article-title":"Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes","volume":"24","author":"Schiller","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib89","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1540-8159.1999.tb06826.x","article-title":"Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient","volume":"22","author":"Huang","year":"1999","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.cjca.2016.01.027_bib90","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood.V97.5.1514","article-title":"Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide","volume":"97","author":"Unnikrishnan","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib91","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.V98.2.266","article-title":"Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide","volume":"98","author":"Westervelt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/mol.66.1.33","article-title":"Mechanisms of arsenic-induced prolongation of cardiac repolarization","volume":"66","author":"Ficker","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib93","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.CIR.0000109484.00668.CE","article-title":"Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents","volume":"109","author":"Drolet","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.027_bib94","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib95","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib96","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib97","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tips.2005.01.003","article-title":"Predicting drug-hERG channel interactions that cause acquired long QT syndrome","volume":"26","author":"Sanguinetti","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cjca.2016.01.027_bib99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00210-010-0496-7","article-title":"Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine","volume":"381","author":"Obers","year":"2010","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.027_bib100","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib101","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib102","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib103","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.10847","article-title":"A\u00a0high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma","volume":"95","author":"Desai","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib104","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J\u00a0Haematol"},{"key":"10.1016\/j.cjca.2016.01.027_bib105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cjca.2016.01.027_bib106","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.2002.20.13.3042","article-title":"Endothelial dysfunction in antiangiogenesis-associated thrombosis","volume":"20","author":"Kaushal","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib107","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.2000.18.10.2169","article-title":"Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature","volume":"18","author":"Weijl","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib108","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.20893","article-title":"Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine","volume":"103","author":"Numico","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib109","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2004.10.023","article-title":"Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer","volume":"96","author":"Jacobson","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1540-8175.2003.03002.x","article-title":"Cisplatin induced localized aortic thrombus","volume":"20","author":"Apiyasawat","year":"2003","journal-title":"Echocardiography"},{"key":"10.1016\/j.cjca.2016.01.027_bib111","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib112","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.1992.tb02978.x","article-title":"Modulation of tissue factor on human monocytes by cisplatin and adriamycin","volume":"81","author":"Walsh","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2016.01.027_bib113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0049-3848(00)00294-2","article-title":"Cisplatin triggers platelet activation","volume":"99","author":"Togna","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.cjca.2016.01.027_bib114","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1592\/phco.22.13.1200.33524","article-title":"Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide","volume":"22","author":"Cool","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjca.2016.01.027_bib115","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000226049","article-title":"Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy","volume":"42","author":"Licciardello","year":"1985","journal-title":"Oncology"},{"key":"10.1016\/j.cjca.2016.01.027_bib116","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cjca.2016.01.027_bib117","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.cjca.2016.01.027_bib118","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2016.01.027_bib119","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2011.04361.x","article-title":"Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke","volume":"9","author":"Nieswandt","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cjca.2016.01.027_bib120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/01.ATV.0000030186.66672.36","article-title":"Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor\/vascular endothelial growth factor receptor pathway in cancer patients","volume":"22","author":"Kuenen","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2016.01.027_bib121","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2016.01.027_bib122","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1200\/JCO.2003.99.046","article-title":"Bevacizumab, bleeding, thrombosis, and warfarin","volume":"21","author":"Kilickap","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib123","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib124","doi-asserted-by":"crossref","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, et\u00a0al. Epic: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML) [abstract 519]. 56th American Society of Hematology Meeting;\u00a02014.","DOI":"10.1182\/blood.V124.21.519.519"},{"key":"10.1016\/j.cjca.2016.01.027_bib125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib126","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cjca.2016.01.027_bib127","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.027_bib128","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/ATVBAHA.112.248500","article-title":"Role of Src tyrosine kinases in experimental pulmonary hypertension","volume":"32","author":"Pullamsetti","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2016.01.027_bib129","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib131","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","article-title":"Chemotherapy-induced pulmonary hypertension: role of alkylating agents","volume":"185","author":"Ranchoux","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cjca.2016.01.027_bib132","first-page":"1055","article-title":"Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide","volume":"20","author":"Groen","year":"1993","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.027_bib133","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1188\/03.CJON.72-75","article-title":"Cardiotoxicity and capecitabine: a case report","volume":"7","author":"Singer","year":"2003","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.cjca.2016.01.027_bib134","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.027_bib136","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib137","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib138","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1378\/chest.06-2360","article-title":"Risk of thrombosis with lenalidomide and its prevention with aspirin","volume":"131","author":"Hirsh","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2016.01.027_bib139","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib140","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A\u00a0randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib141","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib142","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","article-title":"Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis","volume":"108","author":"Zonder","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib143","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J\u00a0Haematol"},{"key":"10.1016\/j.cjca.2016.01.027_bib144","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2016.01.027_bib145","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy","volume":"100","author":"Cavo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib146","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib147","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cjca.2016.01.027_bib148","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4065\/80.12.1549","article-title":"Thalidomide therapy and deep venous thrombosis in multiple myeloma","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2016.01.027_bib149","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib150","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2016.01.027_bib151","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000073282","article-title":"Thalidomide and thrombosis","volume":"33","author":"Rodeghiero","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.cjca.2016.01.027_bib152","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737140.7.3.307","article-title":"Thrombosis in multiple myeloma","volume":"7","author":"Zangari","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cjca.2016.01.027_bib153","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00002018-200124020-00002","article-title":"Thalomid (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing","volume":"24","author":"Clark","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.027_bib154","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s00277-005-1007-7","article-title":"Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival","volume":"84","author":"Schutt","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cjca.2016.01.027_bib155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00063030-200115030-00003","article-title":"Thalidomide in cancer: potential uses and limitations","volume":"15","author":"Singhal","year":"2001","journal-title":"BioDrugs"},{"key":"10.1016\/j.cjca.2016.01.027_bib156","first-page":"491","article-title":"Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review)","volume":"1","author":"Muller","year":"1998","journal-title":"Int J\u00a0Mol Med"},{"key":"10.1016\/j.cjca.2016.01.027_bib157","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib158","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1046\/j.1365-2141.1998.01079.x","article-title":"Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia","volume":"103","author":"Huang","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2016.01.027_bib159","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.leu.2402426","article-title":"Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring","volume":"16","author":"Ohnishi","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.cjca.2016.01.027_bib160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1532\/IJH97.05044","article-title":"Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies","volume":"82","author":"Shigeno","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cjca.2016.01.027_bib161","first-page":"1633","article-title":"Cardiac toxicity of arsenic trioxide","volume":"98","author":"Singer","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2016.01.027_bib162","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.01.027_bib163","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2003.04817.x","article-title":"Cardiac monitoring of patients receiving arsenic trioxide therapy","volume":"124","author":"Unnikrishnan","year":"2004","journal-title":"Br J Haematol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16000672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16000672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T23:14:02Z","timestamp":1718320442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X16000672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":163,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0828282X16000672"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2016.01.027","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2016.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}